Background
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models.• Granzyme K activates the entire complement cascade., PMID:39914456• Granzyme K drives a newly-intentified pathway of complement activation., PMID:38826230• Plasmin as a complement C5 convertase., PMID:27077104• Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein., PMID:2142480• Formation of high affinity C5 convertase of the classical pathway of complement., PMID:12878586• The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation., PMID:19237749• Modulation of classical C3 convertase of complement by tear lactoferrin., PMID:6922088• Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components., PMID:24983375• MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway., PMID:9777418• The human complement system: assembly of the classical pathway C3 convertase., PMID:6906228